Quarterly report [Sections 13 or 15(d)]

CONDENSED CONSOLIDATED BALANCE SHEETS

v3.25.1
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2025
Jun. 30, 2024
Current assets:    
Cash and cash equivalents $ 140,670 $ 151,791
Short-term available-for-sale investments 0 1,072
Accounts receivable, less allowances of $5,888 and $4,386, respectively 237,140 241,394
Inventories 191,083 179,731
Current assets held-for-sale 4,700 9,773
Other current assets 53,647 33,658
Total current assets 627,240 617,419
Property and equipment, net 251,977 251,154
Right-of-use assets 83,744 91,285
Goodwill 968,612 972,663
Intangible assets, net 443,699 507,081
Other assets 268,987 264,265
Total assets 2,644,259 2,703,867
Current liabilities:    
Trade accounts payable 31,644 37,968
Salaries, wages and related accruals 61,896 49,818
Accrued expenses 23,905 24,886
Contract liabilities 32,269 27,930
Income taxes payable 3,628 3,706
Operating lease liabilities - current 14,049 12,920
Other current liabilities 1,813 2,151
Total current liabilities 169,204 159,379
Deferred income taxes 31,924 55,863
Long-term debt obligations 330,000 319,000
Operating lease liabilities 79,450 87,618
Other long-term liabilities 15,656 13,157
Bio-Techne's Shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 400,000,000; issued and outstanding 156,760,717 and 158,216,258 respectively 1,568 1,582
Additional paid-in capital 902,124 820,337
Retained earnings 1,196,385 1,325,247
Accumulated other comprehensive loss (82,052) (78,316)
Total Bio-Techne's shareholders' equity 2,018,025 2,068,850
Total liabilities and shareholders' equity $ 2,644,259 $ 2,703,867